Phio Pharmaceuticals Corp. (PHIO): EBITDA

Operating income plus depreciation and amortization for the same annual period and currency, computed by TickerFacts from the filed figures. Not the company's adjusted EBITDA; a year without both inputs is left out.

-$9.22M

Year ended 2025-12-31

-$13.47M

Trailing 12 months to 2026-06-30

2011-12-31 EBITDA (USD) 2025-12-31

Period ended	EBITDA	Change YoY	Source filing
2025-12-31	-$9.22M	n/m	2026-03-05, From 2025-01-01
2024-12-31	-$7.38M	n/m	2026-03-05, From 2024-01-01
2023-12-31	-$10.77M	n/m	2025-03-31, From 2023-01-01
2022-12-31	-$11.39M	n/m	2024-04-01, From 2022-01-01
2021-12-31	-$13.44M	n/m	2023-03-22, From 2021-01-01
2020-12-31	-$8.72M	n/m	2022-03-22, From 2020-01-01
2019-12-31	-$8.92M	n/m	2021-03-25, From 2019-01-01
2018-12-31	-$7.28M	n/m	2020-03-26, From 2018-01-01
2017-12-31	-$13.99M	n/m	2019-03-27, From 2017-01-01
2016-12-31	-$8.96M	n/m	2018-03-26, From 2016-01-01
2015-12-31	-$10.16M	n/m	2017-03-30, From 2015-01-01
2014-12-31	-$8.74M	n/m	2016-03-30, From 2014-01-01
2013-12-31	-$20.85M	n/m	2015-03-30, From 2013-01-01
2012-12-31	-$12.83M	n/m	2014-03-28, From 2012-01-01
2011-12-31	-$12.61M	n/a	2013-03-29, From 2011-01-01

EBITDA at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

Company	Year ended	EBITDA	Change YoY
Phio Pharmaceuticals Corp. (PHIO)	2025-12-31	-$9.22M	n/m
Emmaus Life Sciences, Inc. (EMMA)	2025-12-31	$270.0K	n/m
Moleculin Biotech, Inc. (MBRX)	2025-12-31	-$25.01M	n/m
Jyong Biotech Ltd. (MENS)	2025-12-31	-$2.51M	n/m
Nexentis Technologies Inc. (NXTS)	2025-12-31	-$4.16M	n/m
Gain Therapeutics, Inc. (GANX)	2025-12-31	-$18.62M	n/m
Faeth Therapeutics, Inc. (FTH)	2025-12-31	-$22.17M	n/m
Galectin Therapeutics Inc (GALT)	2024-12-31	-$42.43M	n/m
Lftd Partners Inc. (LIFD)	2025-12-31	$1.47M	n/m

Compare PHIO, EMMA, MBRX, MENS side by side · Screen every company in Pharmaceutical Preparations ↗